BioNTech SE
BNTX
$101.81
$3.053.09%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -43.89% | 24.59% | -319.53% | -163.51% | -78.83% |
| Total Depreciation and Amortization | 107.83% | 8.59% | 54.68% | 23.47% | 186.30% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -247.62% | -591.61% | 112.01% | 78.85% | 1,225.61% |
| Change in Net Operating Assets | -474.99% | -206.68% | -50.28% | 372.19% | 113.14% |
| Cash from Operations | -153.91% | -179.55% | -63.32% | 52.58% | 8.12% |
| Capital Expenditure | 21.21% | -36.17% | -30.37% | -31.01% | 35.44% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 125.50% | 91.64% | 93.20% | -229.40% | -11,085.02% |
| Cash from Investing | 122.29% | 88.35% | 89.58% | -217.20% | -1,663.80% |
| Total Debt Issued | -- | -- | -- | -- | 0.00% |
| Total Debt Repaid | 40.65% | 15.96% | -143.62% | 16.13% | -33.70% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | 98.56% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 43.97% | 97.43% | 86.14% | 97.29% | 78.99% |
| Foreign Exchange rate Adjustments | 109.63% | -103.80% | -103.58% | 125.40% | 2.84% |
| Miscellaneous Cash Flow Adjustments | -107.45% | -- | -- | -- | 34,826.99% |
| Net Change in Cash | 107.42% | -13.25% | -31.55% | -57.12% | -527.65% |